Brokers Set Expectations for XFOR FY2029 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Investment analysts at Brookline Capital Markets upped their FY2029 earnings per share (EPS) estimates for shares of X4 Pharmaceuticals in a report released on Thursday, August 6th. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings of $0.99 per share for the year, up from their prior forecast of $0.88. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.77) per share.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its earnings results on Friday, August 7th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05. X4 Pharmaceuticals had a negative return on equity of 64.95% and a negative net margin of 568.80%.The business had revenue of $8.81 million during the quarter, compared to analysts’ expectations of $2.42 million.

A number of other research firms have also weighed in on XFOR. Leerink Partners started coverage on shares of X4 Pharmaceuticals in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 price objective for the company. Wells Fargo & Company assumed coverage on shares of X4 Pharmaceuticals in a report on Friday, July 10th. They issued an “overweight” rating and a $11.00 price target for the company. Finally, Weiss Ratings upgraded shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, X4 Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.70.

X4 Pharmaceuticals Stock Performance

Shares of X4 Pharmaceuticals stock opened at $4.25 on Monday. The company has a current ratio of 10.18, a quick ratio of 9.98 and a debt-to-equity ratio of 0.45. The stock’s fifty day moving average price is $4.03 and its 200-day moving average price is $3.95. The firm has a market cap of $400.86 million, a P/E ratio of -3.54 and a beta of 0.37. X4 Pharmaceuticals has a 12 month low of $1.35 and a 12 month high of $4.83.

Hedge Funds Weigh In On X4 Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its holdings in shares of X4 Pharmaceuticals by 20.3% in the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after buying an additional 22,485 shares in the last quarter. Rhumbline Advisers raised its stake in shares of X4 Pharmaceuticals by 5.4% during the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after acquiring an additional 9,690 shares in the last quarter. Jane Street Group LLC lifted its position in X4 Pharmaceuticals by 112.5% during the second quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock valued at $185,000 after acquiring an additional 51,544 shares during the last quarter. Vanguard Group Inc. lifted its position in X4 Pharmaceuticals by 77.0% during the third quarter. Vanguard Group Inc. now owns 410,485 shares of the company’s stock valued at $1,404,000 after acquiring an additional 178,593 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new stake in X4 Pharmaceuticals in the third quarter valued at approximately $47,000. 72.03% of the stock is currently owned by institutional investors.

Insider Activity at X4 Pharmaceuticals

In related news, CFO David Kirske sold 8,543 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $4.26, for a total transaction of $36,393.18. Following the completion of the sale, the chief financial officer directly owned 167,750 shares in the company, valued at $714,615. This represents a 4.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders own 1.13% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.